2023年3月27日,

加州启动编译指示生物提出了1000万美元的股权由加州的编译指示生物,前面tech-enabled药物发现平台称为VastBiome,宣布了1000万美元的额外股本继续发展其专有的方法在人工智能、基因组测序和合成生物学发现生物标志物和新疗法治疗免疫失调。投资者维京全球投资者,默克全球卫生创新基金,和CJ投资参与合资企业集体的圆头(Korean-based战略投资者)。这一轮的公司总风险投资是1500万美元。编译指示生物使用病人数据调查免疫系统之间的关系和身体的自然化学找到新的治疗方法。额外资金将使业务规模操作,加速产品开发,并添加新的团队成员支持编译指示生物的扩张。融资增加,根据编译指示生物的首席执行官卡里姆巴尔古提,“反映了我们的使命揭示了共生性质和人体之间的联系,使我们能够产生天然药物,鼓励我们的幸福。”“著名医疗投资者确认我们的参与方法,旨在确定日常药物创造了自然在我们的身体内。他继续编译指示生物提供了更好的病人正在寻求的解决方案。编译指示生物开发存活率存在发现引擎称为晶格。它通过无数的档案和各种交互和天然化合物之间的相关性和人类细胞与临床结果。接下来,使用尖端技术,生物相关的微生物基因被修改和运送到实验室制造和清单多种酶和天然化学物质。 The business has made significant progress toward scalable enzyme expression and discovering immuno-oncology biomarkers. Pragma Bio has partnered with world authorities in academia and pharmaceuticals. Moreover, Pragma Bio has assembled a group of accomplished drug scouts that have successfully created over $30 billion in exits and launched medications. The Venture Collective’s founding partner, Nick Shekerdemian, stated, “We sincerely feel that the natural world has so much potential for treating diseases for which there are few effective therapy choices. To better patients’ lives globally, we are thrilled to collaborate with the exceptional Pragma team to close the gap between natural goods and thoughtfully developed therapies. “GHIF made its inaugural investment in Pragma Bio in 2020 out of our Next Horizon investment area, which focuses on groundbreaking technology,” stated Prem Tumkosit, Managing Director of the Merck Global Health Innovation Fund (GHIF). We’re happy to continue supporting Pragma Bio in this fundraising, they continued. We try our best to fact-check and bring the best, well-researched, and non-plagiarized content to you. Please let us know -if there are any discrepancies in any of our published stories, -how we can improve, -what stories you would like us to cover and what information you are looking for, in the comments section below or through our contact form! We look forward to your feedback, and thank you for stopping by!